Humanwell Healthcare (SHA:600079) subsidiary Hubei Institute of Biomedical Industry Technology registered its phase 2 clinical trial for its HW211026 ointment for actinic keratosis, according to a Friday filing with the Shanghai bourse.
Actinic keratosis is a precancerous skin lesion brought about by long-term chronic exposure to ultraviolet radiation.
Cumulative research and development spending on the drug has so far reached 43 million yuan.